The safety and efficacy of adding the CCR5 inhibitor maraviroc to pembrolizumab in refractory mismatch-repair-proficient colorectal cancer (MMRp CRC) was assessed in a phase I trial PICCASSO study. The gene discussed is CCR5; the disease is colorectal carcinoma.